Arginase-1 targeting peptide vaccine in patients with metastatic solid tumors – A phase I trial

BACKGROUND: Arginase-1-producing cells inhibit T cell-mediated anti-tumor responses by reducing L-arginine levels in the tumor microenvironment. T cell-facilitated elimination of arginase-1-expressing cells could potentially restore L-arginine levels and improve anti-tumor responses. The activation...

Descripción completa

Detalles Bibliográficos
Autores principales: Lorentzen, Cathrine Lund, Martinenaite, Evelina, Kjeldsen, Julie Westerlin, Holmstroem, Rikke Boedker, Mørk, Sofie Kirial, Pedersen, Ayako Wakatsuki, Ehrnrooth, Eva, Andersen, Mads Hald, Svane, Inge Marie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9622376/
https://www.ncbi.nlm.nih.gov/pubmed/36330525
http://dx.doi.org/10.3389/fimmu.2022.1023023

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9622376/
https://www.ncbi.nlm.nih.gov/pubmed/36330525
http://dx.doi.org/10.3389/fimmu.2022.1023023

Ejemplares similares